Expert Interview
Discussing the recent FDA approval of TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderately to severely active Crohn's disease
Ticker(s): JNJ, ABBV, LLYInstitution: Baylor
- Associate Professor of Medicine-Gastroenterology at Baylor College of Medicine.
- Manages 500 patients with Crohn's disease.
- Research focuses on inflammatory bowel disease (Crohn's disease and ulcerative colitis); PI for GALAXI study at BCM site.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
